Rare Disease Trial, Recruiting (NCT07374692)

Rare Disease Trial, Recruiting NCT07374692 Sponsor: National Cancer Institute (NCI) Condition: Rare Disease

Printed from Voxsanity (voxsanity.com.au) — NCT07374692 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Rare Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

"Who might be able to join this trial:

You have an advanced brain or central nervous system (CNS) tumor that has come back, confirmed by a pathology (tissue) report — this includes certain types of returning brain tumors such as high-grade gliomas or other CNS tumors.
You are already scheduled to have a brain tumor biopsy or surgical removal (resection) at the NIH (National Institutes of Health).
If you have had radiation therapy before, your scheduled biopsy or surgery must be at least 6 months after that radiation treatment ended.
You are 15 years old or older.
You, your parent or guardian, or your legal representative is able to understand and sign a consent form agreeing to take part in the study.

Who may not be able to join:

There are no specific exclusion criteria listed for this trial.

Important: Always verify eligibility with the trial site directly before applying."

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jing Wu, M.D., National Cancer Institute (NCI)

Phone: (240) 858-7330

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07374692

Sponsor: National Cancer Institute (NCI)

Phase: Not Applicable

Status: Recruiting

Condition: Rare Disease

Trial contact: (240) 858-7330

More information: https://clinicaltrials.gov/study/NCT07374692

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

"Who might be able to join this trial:

You have an advanced brain or central nervous system (CNS) tumor that has come back, confirmed by a pathology (tissue) report — this includes certain types of returning brain tumors such as high-grade gliomas or other CNS tumors.
You are already scheduled to have a brain tumor biopsy or surgical removal (resection) at the NIH (National Institutes of Health).
If you have had radiation therapy before, your scheduled biopsy or surgery must be at least 6 months after that radiation treatment ended.
You are 15 years old or older.
You, your parent or guardian, or your legal representative is able to understand and sign a consent form agreeing to take part in the study.

Who may not be able to join:

There are no specific exclusion criteria listed for this trial.

Important: Always verify eligibility with the trial site directly before applying."

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

National Cancer Institute (NCI)

Registry

ClinicalTrials.gov

Start date

4 February 2026

Est. completion

30 December 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To determine the proportion of participants with advanced CNS tumors for whom SmartMatch drug screen analysis results are generated within 21 days from the time of tumor tissue acquisition

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov